I had thought Biomarin-Genzyme-TKT and the like took a long time to get their drugs in Japan because of difficulty getting enough patients for bridging studies... I guess not!!
Would guess that probably means clinical trials enroll faster in Japan too.
Edit: And I hate to say it but the FDA doesn't look so bad (on a relative basis) as I thought.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.